igm
biosciences
initiates
clinical
trial
treatment
solid
cancers
lymphoma
mountain
view
globe
newswire
igm
biosciences
nasdaq
igms
biotechnology
company
focused
creating
developing
engineered
igm
antibodies
today
announced
first
patient
dosed
phase
clinical
trial
evaluating
igm
antibody
targeting
death
receptor
protein
patients
solid
cancers
lymphoma
multicenter
phase
clinical
trial
evaluate
intravenously
administered
monotherapy
combination
chemotherapy
patients
relapsed
refractory
solid
cancers
lymphoma
key
objectives
trial
provide
initial
assessment
pharmacokinetics
safety
biomarkers
preliminary
efficacy
single
agent
combination
standard
care
chemotherapy
igm
expects
report
initial
data
phase
trial
initiation
clinical
trial
another
significant
milestone
igm
development
marks
second
program
proprietary
igm
antibody
platform
begin
clinical
development
said
fred
schwarzer
chief
executive
officer
igm
biosciences
believe
igm
antibodies
potential
overcome
limitations
current
medicines
deliver
new
therapeutic
options
patients
cancer
serious
diseases
hope
pursue
broad
clinical
development
strategy
including
combination
targeted
oncology
igm
antibodies
capacity
multivalent
binding
designed
efficiently
send
apoptotic
signal
cancer
cell
enhance
vitro
potency
killing
cancer
cells
compared
igg
antibodies
binding
units
said
johanna
bendell
chief
development
officer
director
drug
development
program
sarah
cannon
research
institute
tennessee
oncology
look
forward
working
igm
team
pursuit
fully
elucidate
potential
novel
igm
biosciences
headquartered
mountain
view
california
igm
biosciences
biotechnology
company
focused
creating
developing
engineered
igm
antibodies
since
igm
biosciences
worked
overcome
manufacturing
protein
engineering
hurdles
limited
therapeutic
use
igm
antibodies
efforts
igm
biosciences
created
proprietary
igm
technology
platform
development
igm
antibodies
clinical
indications
inherent
properties
may
provide
advantages
compared
igg
antibodies
cautionary
note
regarding
statements
press
release
contains
statements
including
statements
relating
igm
plans
expectations
forecasts
future
events
statements
include
limited
potential
expectations
regarding
company
igm
technology
platform
igm
antibodies
statements
regarding
company
phase
clinical
trial
statements
regarding
company
development
strategy
statements
igm
chief
executive
officer
statements
subject
numerous
important
factors
risks
uncertainties
may
cause
actual
events
results
differ
materially
including
limited
potential
delays
disruption
resulting
pandemic
governmental
responses
pandemic
including
future
impacts
igm
operations
manufacturing
product
candidates
progression
clinical
trials
enrollment
current
future
clinical
trials
collaborations
related
efforts
igm
early
stages
clinical
drug
development
risks
related
use
engineered
igm
antibodies
novel
unproven
therapeutic
approach
igm
ability
advance
product
candidates
successfully
complete
clinical
trials
timelines
projects
risk
necessary
regulatory
approvals
obtained
igm
ability
adequately
demonstrate
sufficient
safety
efficacy
product
candidates
igm
ability
enroll
patients
ongoing
future
clinical
trials
igm
ability
successfully
manufacture
supply
product
candidates
clinical
trials
igm
ability
obtain
additional
capital
finance
operations
needed
uncertainties
related
projections
size
patient
populations
suffering
diseases
igm
targeting
igm
ability
obtain
maintain
protect
intellectual
property
rights
developments
relating
igm
competitors
industry
including
competing
product
candidates
therapies
general
economic
market
conditions
risks
uncertainties
including
fully
described
igm
filings
securities
exchange
commission
sec
including
igm
annual
report
form
filed
sec
march
igm
quarterly
report
form
filed
sec
august
igm
future
reports
filed
sec
statements
contained
press
release
speak
date
hereof
igm
specifically
disclaims
obligation
update
statement
except
required
law
contact
